Utama › Berat Badan Berlebihan › Virginia
Kajian klinikal Berat Badan Berlebihan di Virginia
33 kajian untuk Berat Badan Berlebihan sedang mencari peserta di lokasi di Virginia.
Bandar di Virginia
- Arlington11 kajian
- Richmond9 kajian
- Charlottesville5 kajian
- Newport News5 kajian
- Norfolk4 kajian
- Winchester3 kajian
- Alexandria3 kajian
Teks kajian rasmi (Bahasa Inggeris)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Washington Center For Weight Management And Research /ID# 282047, Arlington
- Sovah Health - Danville /ID# 282876, Danville
- Health Research Of Hampton Roads /ID# 282014, Newport News
- dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- National Clin Res Inc., Richmond
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07533175AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Washington Cntr Weight Mgmt, Arlington
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- National Clin Res Inc., Richmond
- Gastroent Consult of SW VA, Roanoke
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Sovah Clinical Research-River District, Danville
- Clinical Research Partners, LLC, Richmond
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- York Clinical Research, LLC, Norfolk
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Manassas
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07776509A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- VCU Health - Center for Endocrinology Diabetes and Metabolism, Richmond
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Consultants of Southwest Virginia, Roanoke
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06937086A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Manassas
- Research Site, Norfolk
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Inova Cardiology - Fairfax, Fairfax
- Virginia Heart, Falls Church
Mengambil pesertaFasa 3
Umur 45 hingga 99 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Norfolk
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Charlottesville Medical Research, Charlottesville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Sovah Clinical Research-River District, Danville
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Hampton
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Hampton
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Manassas Clinical Research Center, Manassas
- Centricity Research Suffolk Primary Care, Suffolk
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07351058A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Burke
- ACCOMPLISH-2 Research Site, Manassas
- ACCOMPLISH-2 Research Site, Suffolk
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
Umur 18 hingga 79 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Selma Medical Associates, Winchester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Sovah Clinical Research-River District, Danville
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Eastern Virginia Medical School (EVMS) Medical Group, Norfolk
- Clinical Research Partners, LLC, Richmond
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07215559A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
- Selma Medical Associates, Winchester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07745504Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Manassas
- Kailera Clinical Site, Richmond
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Washington Center for Weight Management and Research, Inc, Arlington
- Health Research of Hampton Roads, Newport News
- Selma Medical Associates, Winchester
Mengambil pesertaFasa 3
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Danville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Manassas Clinical Research Center Inc, Manassas
Mengambil pesertaFasa 3
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07684144A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Arlington
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Health Res of Hampton Roads, Newport News
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT07509307Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- Children's Hospital of Richmond at VCU Healthy Lifestyles Center, Henrico
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 4 ke atas · Semua jantina · Dikemas kini 10 Jun 2026 · NCT06714929Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes
- University of Virginia, Charlottesville
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 21 hingga 50 · Semua jantina · Dikemas kini 7 Mei 2026 · NCT07573228Examining Valence-based Effects in Self-Monitoring Feedback Messages
- University of Virginia, Charlottesville
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Mac 2026 · NCT07292389Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes
- University of Virginia, Charlottesville
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 30 hingga 55 · Semua jantina · Dikemas kini 23 Mac 2026 · NCT04791371Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status
- UVA Student Health and Wellness Building, Charlottesville
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Dis 2025 · NCT06009276Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.